Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
62,337,402
-
Total 13F shares
-
45,935,957
-
Share change
-
-6,596,579
-
Total reported value
-
$27,556,513
-
Put/Call ratio
-
3942%
-
Price per share
-
$0.60
-
Number of holders
-
67
-
Value change
-
-$42,322,821
-
Number of buys
-
36
-
Number of sells
-
45
Institutional Holders of Elevation Oncology, Inc. - Common Stock, par value $0.0001 per share (ELEV) as of Q3 2024
As of 30 Sep 2024,
Elevation Oncology, Inc. - Common Stock, par value $0.0001 per share (ELEV) was held by
67 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
45,935,957 shares.
The largest 10 holders included
Frazier Life Sciences Management, L.P., TANG CAPITAL MANAGEMENT LLC, GOLDMAN SACHS GROUP INC, FARALLON CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, BVF INC/IL, BlackRock, Inc., Aisling Capital Management LP, RENAISSANCE TECHNOLOGIES LLC, and Hudson Bay Capital Management LP.
This page lists
67
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.